Paraneoplastic syndromes and rheumatic diseases
Journal Title: Advances in Hygiene and Experimental Medicine - Year 2014, Vol 68, Issue
Abstract
Paraneoplastic syndromes, which are discussed in this paper, are a heterogeneous group of disorders associated with cancer, but not directly caused by the physical effects of the primary tumor or its metastases. May precede the appearance of the malignant process, occur simultaneously or disclose in the course of cancer. Paraneoplastic syndromes may be caused directly by toxins produced by tumor cells, occur in the course of hypersensitivity reactions, or be the result of release of intracellular antigens. Due to the often similar systemic symptoms it is very important to evaluate the association of rheumatic diseases and cancer. Most paraneoplastic rheumatologic syndroms are difficult distinguishable from idiopathic rheumatologic disorders. The most common paraneoplastic syndromes include rheumatoid arthritis (RA)-like syndrome arthritis, inflammatory myopathies, hypertrophic osteoarthropathy, vasculitis and Raynaud’s phenomenon.
Authors and Affiliations
Jerzy Świerkot, Aleksandra Lewandowicz-Uszyńska, Katarzyna Bogunia-Kubik
Keywords
Related Articles
- EP ID EP67441
- DOI -
- Views 138
- Downloads 0
The role of intestinal microbiota in irritable bowel syndrome
In recent years, impressive advances in the knowledge about a vast number of microbes living in the human body and interactions between the microbiota and the human body have been observed. All micro-organisms that live...
Aspects of pericytes and their potential therapeutic use
Pericytes, which are multi-potential stem cells, co-create the walls of the microvessels: capillaries, terminal arterioles and postcapillary venules. These cells are localized under the basement membrane, tightly encircl...
Mechanisms of angiogenesis in neoplasia
Mechanism of forming new capillary from basal vessels, named angiogenesis, exist under both physiological and pathological conditions. Initiation of this process requires imbalance between proangiogenic and antiangiogeni...
Biological therapies in systemic lupus erythematosus
The prevention of chronic organic damage and complete inhibition of inflammatory activity of the disease are the main goals in the treatment of systemic lupus erythematosus (SLE). Current therapies of SLE are not effect...
Porównanie glikozylacji haptoglobiny i α1–kwaśnej glikoproteiny w surowicy pacjentów z drobnokomórkowym i niedrobnokomórkowym rakiem płuca